Author details

Full Name

Yongjoon Suh

Affiliation

Research Institute for Natural Sciences, Hanyang University

ORCID

Career Start Year

2007

Papers

H Index

Expertise

CM4AI Collaborator

Kirsten Obernier (CM4AI)

PMID	Paper Title	Journal Title	Published Year
34813169	Soluble ICAM-1 a Pivotal Communicator between Tumors and Macrophages, Promotes Mesenchymal Shift of Glioblastoma.	Adv Sci (Weinh)	2022
34285182	Loss of FBXL14 promotes mesenchymal shift and radioresistance of non-small cell lung cancer by TWIST1 stabilization.	Signal Transduct Target Ther	2021
32179921	Crosstalk between GBM cells and mesenchymal stemlike cells promotes the invasiveness of GBM through the C5a/p38/ZEB1 axis.	Neuro Oncol	2020
32531055	Corrigendum to: Crosstalk between GBM cells and mesenchymal stemlike cells promotes the invasiveness of GBM through the C5a/p38/ZEB1 axis.	Neuro Oncol	2020
30515725	Proinvasive extracellular matrix remodeling for tumor progression.	Arch Pharm Res	2019
29348460	FYN promotes mesenchymal phenotypes of basal type breast cancer cells through STAT5/NOTCH2 signaling node.	Oncogene	2018
29559744	Proinvasive extracellular matrix remodeling in tumor microenvironment in response to radiation.	Oncogene	2018
29301607	Force-mediated proinvasive matrix remodeling driven by tumor-associated mesenchymal stem-like cells in glioblastoma.	BMB Rep	2018
27841864	Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells.	Oncogene	2017
27903965	Tumor-associated mesenchymal stem-like cells provide extracellular signaling cue for invasiveness of glioblastoma cells.	Oncotarget	2017
26700818	PKCÎ´ activated by c-MET enhances infiltration of human glioblastoma cells through NOTCH2 signaling.	Oncotarget	2016
27462787	Radiation driven epithelial-mesenchymal transition is mediated by Notch signaling in breast cancer.	Oncotarget	2016
25533622	Radiation promotes malignant phenotypes through SRC in breast cancer cells.	Cancer Sci	2015
26515758	Beneficial effects of low dose radiation in response to the oncogenic KRAS induced cellular transformation.	Sci Rep	2015
27308397	KRAS-driven ROS promote malignant transformation.	Mol Cell Oncol	2015
25843036	Novel anticancer activity of phloroglucinol against breast cancer stem-like cells.	Toxicol Appl Pharmacol	2015
25854938	Persistent activation of STAT3 by PIM2-driven positive feedback loop for epithelial-mesenchymal transition in breast cancer.	Cancer Sci	2015
25633745	Activation of KRAS promotes the mesenchymal features of basal-type breast cancer.	Exp Mol Med	2015
25620212	Radiation treatment and cancer stem cells.	Arch Pharm Res	2015
25639867	Radiation promotes invasiveness of non-small-cell lung cancer cells through granulocyte-colony-stimulating factor.	Oncogene	2015
25746003	PKCÎ´ maintains phenotypes of tumor initiating cells through cytokine-mediated autocrine loop with positive feedback.	Oncogene	2015
25456733	Phloroglucinol suppresses metastatic ability of breast cancer cells by inhibition of epithelial-mesenchymal cell transition.	Cancer Sci	2015
24632950	Novel signaling axis for ROS generation during K-Ras-induced cellular transformation.	Cell Death Differ	2014
25109450	Radiation promotes malignant progression of glioma cells through HIF-1alpha stabilization.	Cancer Lett	2014
23160379	Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells.	Oncogene	2013
23714583	Fractionated radiation-induced nitric oxide promotes expansion of glioma stem-like cells.	Cancer Sci	2013
23707634	A novel 2-pyrone derivative, BHP, impedes oncogenic KRAS-driven malignant progression in breast cancer.	Cancer Lett	2013
21849886	A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, synergistically enhances radiation sensitivity in human cervical cancer cells.	Anticancer Drugs	2012
22511756	PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population.	J Biol Chem	2012
22648970	A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.	Mol Pharmacol	2012
22249269	c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells.	Oncogene	2012
22266926	An open system for automatic home-cage behavioral analysis and its application to male and female mouse models of Huntington's disease.	Behav Brain Res	2012
22419868	Titanium dioxide induces apoptotic cell death through reactive oxygen species-mediated Fas upregulation and Bax activation.	Int J Nanomedicine	2012
21642840	Triterpenoid pristimerin synergizes with taxol to induce cervical cancer cell death through reactive oxygen species-mediated mitochondrial dysfunction.	Anticancer Drugs	2011
21878493	Importance of PKCÎ´ signaling in fractionated-radiation-induced expansion of glioma-initiating cells and resistance to cancer treatment.	J Cell Sci	2011
21514314	Eckol suppresses maintenance of stemness and malignancies in glioma stem-like cells.	Toxicol Appl Pharmacol	2011
21704033	The small GTPase Rac1 is involved in the maintenance of stemness and malignancies in glioma stem-like cells.	FEBS Lett	2011
20417282	Multipotent precursors in the anterior and hippocampal subventricular zone display similar transcription factor signatures but their proliferation and maintenance are differentially regulated.	Mol Cell Neurosci	2010
19683576	Interaction between DLX2 and EGFR regulates proliferation and neurogenesis of SVZ precursors.	Mol Cell Neurosci	2009
24692909	Differential effect of Dlx2 in neural precursors derived from the anterior and hippocampal SVZ.	J Stem Cells Regen Med	2007

1 - 40 of 40

Jin-Ku Lee

Seoul National University, College of Medicine

Career Start Year 2010

Number of shared co-authors 1

Helen He Zhu

Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine

Career Start Year 2009

Number of shared co-authors 0

Ruby Yun-Ju Huang

National Taiwan University College of Medicine

Career Start Year 2008

Number of shared co-authors 0

Young K Song

National Cancer Institute, National Institutes of Health

Career Start Year 2007

Number of shared co-authors 0

Xiaoyong Huang

Medical College, Yan'an University

Career Start Year 2007

Number of shared co-authors 0

Yun Jee Seo

Institute for Refractory Cancer Research, Samsung Medical Center

Career Start Year 2004

Number of shared co-authors 0

Anita B Hjelmeland

University of Alabama at Birmingham

Career Start Year 2004

Number of shared co-authors 0

Nehad M Alajez

College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation

Career Start Year 2004

Number of shared co-authors 0

Hae-Yun Jung

College of Life Science, CHA University

Career Start Year 2003

Number of shared co-authors 0

Bo Hu

Northwestern University Feinberg School of Medicine

Career Start Year 2003

Number of shared co-authors 0

Mirko H H Schmidt

Institute of Anatomy, Technische Universitat Dresden School of Medicine

Career Start Year 2001

Number of shared co-authors 0

Jeongwu Lee

Lerner Research Institute, Cleveland Clinic

Career Start Year 2001

Number of shared co-authors 1

Yong Jae Shin

Cancer Stem Cell Research Center, Samsung Biomedical Research Institute

Career Start Year 2001

Number of shared co-authors 1

Hye Jin You

Research Institute, National Cancer Center

Career Start Year 2000

Number of shared co-authors 0

Fan Yang

West China Second Hospital, Sichuan University

Career Start Year 2000

Number of shared co-authors 0

Agnieszka Bronisz

Mossakowski Medical Research Institute, Polish Academy of Sciences

Career Start Year 1999

Number of shared co-authors 0

Krishna P Bhat

Department of Neurosurgery at the University of Texas MD Anderson Cancer Center

Career Start Year 1998

Number of shared co-authors 0

Marc Vooijs

Maastricht University Medical Centre+

Career Start Year 1997

Number of shared co-authors 0

Jun Yao

The University of Texas MD Anderson Cancer Center

Career Start Year 1997

Number of shared co-authors 0

Erxi Wu

Livestrong Cancer Institutes, Dell Medical School, The University of Texas at Austin

Career Start Year 1997

Number of shared co-authors 0

Yaoqi Alan Wang

The University of Texas MD Anderson Cancer Center

Career Start Year 1997

Number of shared co-authors 0

Shi-Yuan Cheng

Northwestern University Feinberg School of Medicine

Career Start Year 1996

Number of shared co-authors 0

Suyun Huang

Virginia Commonwealth University

Career Start Year 1993

Number of shared co-authors 0

Jan Paul Medema

Oncode Institute

Career Start Year 1993

Number of shared co-authors 0

Jeremy N Rich

UPMC Hillman Cancer Center, University of Pittsburgh Medical Center

Career Start Year 1992

Number of shared co-authors 0

Frank B Furnari

University of California San Diego

Career Start Year 1992

Number of shared co-authors 0

Oliver B??gler

American Association for Cancer Research, Henry Ford Hospital, Ludwig Institute for Cancer Research, National Cancer Institute, Salk Institute for Biological Studies, University of Cambridge, University of Texas MD Anderson Cancer Center, Virginia Commonwealth University

Career Start Year 1990

Number of shared co-authors 1

Qimin Zhan

Peking University Cancer Hospital

Career Start Year 1989

Number of shared co-authors 0

Wei Zhang

The University of Texas MD Anderson Cancer Center

Career Start Year 1988

Number of shared co-authors 0

Lori S Hart

Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research